Show simple item record

dc.contributor.authorDalen, Dag Morten
dc.contributor.authorLocatelli, Marilena
dc.contributor.authorSorisio, Enrico
dc.contributor.authorStrøm, Steinar
dc.date.accessioned2014-06-02T13:05:27Z
dc.date.available2014-06-02T13:05:27Z
dc.date.issued2014
dc.identifier.citationApplied Economics and Finance, 1(2014)1: 39-54nb_NO
dc.identifier.issn2332-7294
dc.identifier.urihttp://hdl.handle.net/11250/195740
dc.descriptionThis is an open access journal available at redfame.comnb_NO
dc.description.abstractTNF-alpha inhibitors represent one of the most important areas of biopharmaceuticals by sales, with threeblockbusters accounting for 8 per cent of total pharmaceutical sale in Norway. Novelty of the paper is to examine, with the use of a unique natural policy experiment in Norway, to what extent the price responsiveness of prescription choices is affected when the identity of the third-party payer changes. The three dominating drugs in this market, Enbrel, Remicade, and Humira, are substitutes, but have had different and varying funding schemes -hospitals and the national insurance plan. A stochastic structural model for the three drugs, covering demand and price setting, is estimated in a joint maximum likelihood approach. We find that doctors are more responsive when the costs are covered by the hospitals compared to when costs are covered by national insurancenb_NO
dc.language.isoengnb_NO
dc.publisherRedFame Publishingnb_NO
dc.subjectPharmaceuticalsnb_NO
dc.subjectdiscrete choice modelnb_NO
dc.subjectfunding-schemesnb_NO
dc.titleDoes the identity of the third-party payer matter for prescribing doctors?nb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.source.pagenumber39-54nb_NO
dc.source.volume1nb_NO
dc.source.journalApplied Economics and Financenb_NO
dc.source.issue1nb_NO
dc.identifier.doi10.11114/aef.v1i1.324
dc.description.localcodeOAnb_NO


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record